Literature DB >> 16894313

Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection.

Perdita Wietzke-Braun1, Adil B Maouzi, Larissa B Mänhardt, Heike Bickeböller, Giuliano Ramadori, Sabine Mihm.   

Abstract

OBJECTIVE: Interferon-alpha (IFN-alpha), an important mediator for the host's innate antiviral defense system, has been approved for the treatment of persistent viral infections. We investigated whether two functional polymorphisms in genes involved in IFN-alpha signaling and effector functions are associated with the natural outcome of hepatitis C virus (HCV) infection and the responsiveness of chronic hepatitis C patients to IFN-alpha therapy.
METHODS: Forty-four individuals who had resolved HCV infection spontaneously and 147 patients who developed chronic hepatitis C were analyzed for functional single nucleotide polymorphisms in the promoter regions of the interferon regulatory factor-1 (IRF-1) and myxovirus resistance protein-1 (MxA) genes at positions -300 and -88, respectively.
RESULTS: With regard to -300 IRF-1 or -88 MxA genotype distributions or minor allele frequencies, individuals who spontaneously resolved the infection displayed no significant difference compared with those with chronic infections. Among patients with chronic infections, however, the -300AA IRF-1 genotype, associated with a higher IRF-1 transcriptional activity, was absent in patients with chronic HCV genotype 3a infections, with one exception. In contrast to expectations, -300AA IRF-1 individuals with HCV genotype 3a infection were not represented in higher numbers among those with self-limited infections. Regarding IFN-alpha therapy, -300AA IRF-1 chronic hepatitis C genotype 1 patients tend to respond more often than those with the other IRF-1 genotypes.
CONCLUSION: Our findings suggest the possibility that the -300AA IRF-1 genotype is associated with outcome in patients with HCV genotype 3 infection. In addition, in HCV genotype-1-infected patients, this genotype appears associated with response to therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16894313     DOI: 10.1097/01.meg.0000224478.89545.76

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  8 in total

1.  Endotoxin receptor CD14 gene variants and histological features in chronic HCV infection.

Authors:  Eva Askar; Giuliano Ramadori; Sabine Mihm
Journal:  World J Gastroenterol       Date:  2009-08-21       Impact factor: 5.742

2.  Innate immunity and hepatitis C virus infection: a microarray's view.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Infect Agent Cancer       Date:  2012-03-26       Impact factor: 2.965

3.  ENCODE tiling array analysis identifies differentially expressed annotated and novel 5' capped RNAs in hepatitis C infected liver.

Authors:  Milan E Folkers; Don A Delker; Christopher I Maxwell; Cassie A Nelson; Jason J Schwartz; David A Nix; Curt H Hagedorn
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

4.  Role of host genetic factors in the outcome of hepatitis C virus infection.

Authors:  Bertram Bengsch; Robert Thimme; Hubert E Blum
Journal:  Viruses       Date:  2009-08-05       Impact factor: 5.818

5.  Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy.

Authors:  Ahmad Amanzada; Armin Goralczyk; Federico Moriconi; Martina Blaschke; Inga-Marie Schaefer; David van Thiel; Sabine Mihm; Giuliano Ramadori
Journal:  Dig Dis Sci       Date:  2011-10-13       Impact factor: 3.199

Review 6.  Dendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle?

Authors:  Mohit Sehgal; Zafar K Khan; Andrew H Talal; Pooja Jain
Journal:  Virology (Auckl)       Date:  2013-02-11

7.  Bioinformatics analysis of hepatitis C virus genotype 2a-induced human hepatocellular carcinoma in Huh7 cells.

Authors:  Ping Xu; Meiying Wu; Hui Chen; Junchi Xu; Minjuan Wu; Ming Li; Feng Qian; Junhua Xu
Journal:  Onco Targets Ther       Date:  2016-01-08       Impact factor: 4.147

8.  Reducing IRF-1 to Levels Observed in HESN Subjects Limits HIV Replication, But Not the Extent of Host Immune Activation.

Authors:  Ruey-Chyi Su; Andrew Plesniarski; Zhujun Ao; Joshua Kimani; Aida Sivro; Walter Jaoko; Frank A Plummer; Xiaojian Yao; Terry Blake Ball
Journal:  Mol Ther Nucleic Acids       Date:  2015-10-27       Impact factor: 10.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.